Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been assigned an average rating of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.89.

A number of equities research analysts recently commented on YMAB shares. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. State Street Corp lifted its position in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the period. Caligan Partners LP lifted its holdings in shares of Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the period. Geode Capital Management LLC boosted its position in shares of Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Price Performance

YMAB opened at $8.78 on Monday. The stock’s 50 day simple moving average is $12.69 and its 200 day simple moving average is $12.65. The stock has a market cap of $393.25 million, a P/E ratio of -16.26 and a beta of 0.61. Y-mAbs Therapeutics has a 1-year low of $6.09 and a 1-year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same period last year, the company posted ($0.18) EPS. Research analysts expect that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.